Overview
Northwest Healthcare Q2 2025 revenue falls 16.9% to C$99 million due to asset sales
Net income for Q2 2025 reaches C$32.6 mln, reversing prior year loss
Co suspends DRIP and appoints CEO Zachary Vaughan to Board
Outlook
Company manages rent deferral with Healthscope, expecting repayment by March 2026
Result Drivers
ASSET SALES - Revenue decreased 16.9% in Q2 2025 due to non-core asset sales, partially offset by same property revenue growth
SPNOI GROWTH - Same Property Net Operating Income increased by 2.8% driven by inflationary rent adjustments and improved recoveries
DEBT REDUCTION - Proceeds from asset sales used to repay debt, reducing leverage to 48.5% from 50.0% at year-end 2024
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income | C$32.62 mln | ||
Q2 FFO Per Share | C$0.11 |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the specialized reits peer group is "buy."
Wall Street's median 12-month price target for Northwest Healthcare Properties REIT is C$5.55, about 14.2% above its August 11 closing price of C$4.76
Press Release: ID:nNFC5HMZvh
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。